Inaugurated last Friday (May 17), the Pasteur Fiocruz Center on Immunology and Immunotherapy, located at Fiocruz Ceará, brings together scientists from the France-based Institut Pasteur and Brazil’s Fiocruz, two members of the Pasteur Network, to develop an integrative approach towards immunotherapies applied to both infectious and non-communicable diseases.
This scientific cooperation aims to accelerate research in immunology and immunotherapy (I-I) at regional, national, and international levels. It counts on the support of the Ceará state government and the French Ministry for Europe and Foreign Affairs, through its Embassy in Brasilia.
The Center has three priority scientific areas: cancer; infectious and neglected diseases; autoimmune, neurodegenerative and inflammatory diseases. Among the projects hosted by the Center are: the development of integrin inhibitors for treating neurodegenerative diseases; the development of antibody-drug conjugates (ADCs); the development of nanobody/antibody fragments for neglected tropical diseases; CAR-T cells; and immunotherapies to enhance T cell functions to tackle infectious diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze